摘要
目的评价纤溶酶与三七总皂苷对比治疗急性脑梗死的疗效及安全性。方法急性脑梗死患者120例，应用投掷硬币法随机分为纤溶酶组与三七总皂苷组各60例，纤溶酶组给予纤溶酶治疗，三七总皂苷组给予三七总皂苷治疗，疗程均为14d，观察其临床疗效及神经功能缺损评分的变化。结果纤溶酶组显效36例（60．0％）及有效55例（91．7％）均明显高于三七总皂苷组的25例（41．7％）及46例（76．7％），差异有统计学意义（P〈0．05），2组神经功能缺损评分比较差异有统计学意义（P〈0．01或P〈0．05）。纤溶酶治疗后纤维蛋白原和血小板聚集率明显下降（P〈0．01），而对凝血酶原时间无明显延长。结论纤溶酶是溶栓治疗发病72h内急性脑梗死患者的一种疗效好、安全性高的药物。
Objective To evaluate efficacy and safety of fibrinolysin for patient with acute cerebral infarction. Methods One hundred and twenty patient with acute cerebral infarction were randomly divided into treatment group （fibrinolysin group） and control group （Xuesaitong group）. The curative effect and neurological functional deficit were observed after trentment for 14 days. Results Both excellence rate （60.0%） and effective rate （91.7%）of treatment group were significantly higher than these of control group （P 〈 0. 05 ）. There was significant difference of neurological functional deficit scale between two groups （P 〈 0.01 ）. Fibrinogen and platelet aggregation rate decreased significantly after fibrinolysin treatment, furthermore the prothrombin time was not prolonged. Conclusion Compared with Xuesaitong, Fibrinolysin shows better curative effect and higher safety for patient with acute cerebral infarction within 7 hours.
出处
《中国医药》
2009年第2期93-94,共2页
China Medicine
关键词
脑梗死
纤溶酶
Cerebral infarction
Fibrinolysin
